China Builds World’s Biggest Vaccine Plant,100 Million Dose Capacity to Be Used for COVID-19 Vaccine


A leading state-owned enterprise in China has just built the world’s largest vaccine plant, as researchers around the globe scramble to develop effective measures for dealing with COVID-19.

China Electronics Corporation (中国电子信息产业集团) recently announced that subsidiary Fourth Construction Co., Ltd. of China Electronics System Engineering (中国电子系统工程第四建设有限公司) had just completed work on China’s first P3 biosafety level (BSL-3) pharmaceutical production facility.

The facility is ready to commence operation, and will be used for the production of a Novel Coronavirus vaccine. According to its developers the plant will have an annual production capacity of 100 million doses.

State media said that the construction of the new plant marks a major advance for the Chinese biotech sector, given that China currently lacks its own domestic standards for the construction of human-use bio-facilities.

BSL-3 facilities are approved for operations involving microbes that are capable of causing severe and potentially lethal diseases, and can be contracted via inhalation.

Fourth Construction was primarily responsible for structural steel design and construction of the facility, as well as air conditioning engineering and water supply systems.

The Hebei-based company was founded in 1953 and is China’s leading construction contractor for P3 facilities, with a market share of over 80% for major building projects involving international biotech companies.

At a press con­fer­ence held on 18 March Zhong Nan­shan (钟南山), a se­nior ex­pert with Chi­na’s Na­tional Health Com­mis­sion (国家卫生健康委) said that China was in the process of work­ing on five dif­fer­ent types of Novel Coronavirus vac­cines, in­clud­ing a whole virus vac­cine, a nu­cleic acid vac­cine, an ade­n­ovirus vac­cine, a pro­tein vac­cine in­volv­ing ge­netic en­gi­neer­ing, and an in­fluenza vac­cine. 

Zhong also said that China was “rac­ing” to de­velop a vac­cine by Sep­tem­ber in ad­vance of the US, and that a prod­uct would be ready around that time. 

In March human testing commenced in Wuhan for a COVID-19 vac­cine that was de­vel­oped by the Acad­emy of Mil­i­tary Med­ical Sci­ences in collaboration Hong Kong-listed CanSino Bio-B. 

Related stories

China Sheds Light on Se­lec­tion Process for COVID-19 Vac­cine Vol­un­teers, Says Prod­uct Could be Ready by Sep­tem­ber

First Group of COVID-19 Vac­cine Test Sub­jects Re­turn Home in Wuhan

108 Vol­un­teers Sign up for Stage 1 COVID-19 Vac­cine Tri­als in Wuhan Held by CanSino Bio-B